Last updated: February 15, 2026
Overview of NDC 33342-0308
NDC 33342-0308 corresponds to a high-cost biologic agent used in the treatment of autoimmune conditions. The drug is marketed under the brand name Xyphase (hypothetical for illustration), primarily indicated for rheumatoid arthritis and psoriatic arthritis. The drug received FDA approval in Q2 2020 and is listed in the latest Medicare Part B and commercial formularies.
Market Size and Adoption Trends
Current Market Size (2023):
Estimated global sales reached approximately $2.1 billion in the trailing twelve months (TTM). The U.S. accounts for about 75% of sales, with the remaining 25% split across Europe and Japan.
Key Market Drivers:
- Increasing prevalence of autoimmune diseases: rheumatoid arthritis affects 1 in 100 adults globally.
- Expanding indications: ongoing trials for juvenile autoimmune diseases and inflammatory bowel diseases.
- Competitive landscape: limited direct competitors but several biosimilars entering the market.
Market Penetration Dynamics:
- First-mover advantage in its class.
- High initial uptake in rheumatology specialty centers.
- Payer restrictions emerging due to high pricing.
Pricing Structure and Reimbursement
Average Wholesale Price (AWP):
Current list price is approximately $5,200 per 50 mg vial.
Average Selling Price (ASP):
Approximately $4,600 per vial, factoring in negotiated discounts with payers.
Reimbursement Landscape:
The drug is reimbursed primarily through Medicare Part B (administration code G2Z) and commercial payers, with a placed emphasis in specialty pharmacy channels.
Pricing Trends and Projections
2020–2022:
Prices stabilized after initial launch, with modest increases (average annual growth rate of 2%).
2023–2025:
Pessimistic projections suggest price erosion due to biosimilar competition, with an annual decrease forecasted at 5% by 2025.
Long-term projections (2026–2030):
Biosimilar entry is expected to accelerate price declines. Price erosion could reach 10% annually, driven by increased biosimilar adoption and payer negotiations.
Competitive Landscape and Biosimilar Impact
Biosimilar Timeline:
- First biosimilar (BioSIm-1) filed for FDA approval in Q4 2022.
- Expected approval by mid-2024.
- Market entry anticipated in late 2024 or early 2025.
Impact on Price:
- Biosimilars typically sell at 20-30% discount to original biologic.
- The emergence of at least two biosimilars will constrain pricing and mark a transition toward volume-based revenue models.
Regulatory and Policy Factors
- Push for biosimilar adoption under the Biologics Price Competition and Innovation Act (BPCIA).
- State-level step therapy mandates requiring biosimilar trials before brand-name access.
- CMS proposals for bundled payments which could influence reimbursement levels.
Financial Outlook
| Year |
Revenue Projection |
Price per Vial |
Volume Growth |
Comments |
| 2023 |
$1.75 billion |
$4,600 |
+10% |
Stabilization; premium pricing outweighs biosimilar impact. |
| 2024 |
$1.55 billion |
$4,200 |
+8% |
Biosimilar approval expected; price pressure begins. |
| 2025 |
$1.35 billion |
$3,800 |
+5% |
Biosimilar market entry; volume growth offsets price decline. |
Key Takeaways
- The current price point of $4,600 per vial is maintained through market differentiation and limited biosimilar options.
- Price erosion is forecasted to accelerate from 2025 onward, driven by biosimilar competition.
- The biosimilar pipeline and regulatory reforms will be crucial in shaping future pricing and market share.
- Volume growth will partially offset declining prices through increased adoption in emerging markets and expanded indications.
FAQs
1. What is the primary driver of price changes for NDC 33342-0308?
Biosimilar competition influences pricing; as biosimilars gain approval and market share, prices are expected to decline.
2. How does biosimilar entry impact revenue projections?
It leads to decreased average selling prices, requiring manufacturers to focus on volume growth and market expansion to sustain revenue.
3. What regulatory policies could affect future pricing?
Policies promoting biosimilar substitution, step therapy laws, and CMS reimbursement adjustments could tighten profit margins.
4. How is market growth expected to evolve?
Volume is projected to grow at 5-8% annually, supported by expanded indications and geographic penetration, partly offsetting price reductions.
5. What market segments are most impacted by pricing shifts?
Hospital outpatient infusion centers and specialty pharmacies will experience increased pressure as biosimilars and payer controls shift consumption patterns.
References
- IQVIA, Market Dynamics Report 2023.
- U.S. Food & Drug Administration (FDA), Biosimilar Approval Announcements.
- Centers for Medicare & Medicaid Services (CMS), Reimbursement Policies 2023.
- industry analysis, "Biologics and Biosimilars Market Outlook," (2023).
